S&P・Nasdaq 本質的価値 お問い合わせ

XORTX Therapeutics Inc. XRTX NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • CA • USD

SharesGrow Score
49/100
2/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

XORTX Therapeutics Inc. (XRTX) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.

アナリスト予想 一株当たり利益(EPS) $-1.50 および 売上高 $0.00B 来期予想.

一株当たり利益(EPS)実績推移: 2024: 実績 $-7.90 vs 予想 $-1.50 (下回る -426.7%). 2025: 実績 $-3.90 vs 予想 $-0.69 (下回る -465.1%). アナリスト精度: 18%.

EPS予測 — XRTX

18%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024 Actual –$7.90 vs Est –$1.50 ▼ 81.0% off
2025 Actual –$3.90 vs Est –$0.69 ▼ 82.3% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.

売上高予測 — XRTX

Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
お問い合わせ
🎓
SharesGrow アカデミー
本質的価値の計算と割安株の見つけ方を学ぶ。
毎週のライブセッション
メッセージを送る